Week of July 30, 2012: FDA Issues Complete Response Letter to Luitpold Pharmaceuticals for Injectafer NDA; Novasep Invests to Expand API Manufacturing Capabilities; and More - Pharmaceutical

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of July 30, 2012: FDA Issues Complete Response Letter to Luitpold Pharmaceuticals for Injectafer NDA; Novasep Invests to Expand API Manufacturing Capabilities; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Cleveland BioLabs has signed a contract valued at 139 million Russian rubles ($4 million) with the Ministry of Industry and Trade of the Russian Federation for development of CBLB612, a drug in development for stimulation of hematopoietic stem-cell proliferation and mobilization. The contract provides funding over a period of approximately three years, which will be used to support completion of preclinical studies, filing of an investigational new drug application, and Phase I and II clinical studies. The contract was issued by Russia’s Pharma 2020 plan, a government initiative to stimulate pharmaceutical-based economic development. Read More

FDA has issued a Complete Response Letter to Luitpold Pharmaceuticals, part of Daiichi Sankyo, for the company’s Sept. 30, 2011, new drug application (NDA) for Injectafer (ferric carboxymaltose injection), for treating iron deficiency anemia. In the Complete Response Letter, FDA noted its decision to withhold approval at this time. The decision was not related to any issues with the Injectafer NDA filing, but with Luitpold’s manufacturing facility in Shirley, New York. During a recent inspection, FDA inspectors noted issues in the facility where Injectafer is manufactured for the US market. Luitpold Pharmaceuticals said it’s working with FDA to resolve the issues found in the recent inspection. Read More

Novasep has announced a EUR 3-million ($3.69 million) investment to expand its highly potent API manufacturing capabilities at its Le Mans, France, facility. The expansion is expected to be fully operational by the beginning of 2013. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here